Compare Mesoblast Limited (MESO) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Rambus Inc. Common Stock — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Rambus Inc. Common Stock trades at $89.17 (market cap $10.66B). The key difference: Rambus Inc. Common Stock is far larger — about 5.8× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (259,445 versus 2,136,075). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Rambus Inc. Common Stock for 0 Days on average.
| MESO | RMBS | |
|---|---|---|
Market Cap | $1.83B | $10.66B |
Volume | 259,445 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $20.96 | $170.66 |
52-Week Low | $13.19 | $79.73 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.91B | $9.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
